NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDSemaglutide Wegovy®
(0.25mg, 0.5mg, 1mg, 1.7mg & 2.4mg solution for injection in pre-filled pen) 		Central nervous system, Drugs used in the treatment of obesity, 04.05
GREENSemaglutide 0.25mg, 0.5mg, 1mg Ozempic®
(pre-filled pen) 		Endocrine system, GLP-1 mimetics, 06.01.02.03
GREENSemaglutide Oral Tablets Rybelsus® Endocrine system, GLP-1 mimetics, 06.01.02.03
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Semaglutide Semaglutide Endocrine System, Blood Glucose Lowering Drugs, Glucagon-Like Peptide-1 Receptor Agonists
Diabetes Mellitus And Hypoglycaemia, Diabetes Mellitus
Semaglutide Semaglutide Gastro-Intestinal System, Blood Glucose Lowering Drugs, Glucagon-Like Peptide-1 Receptor Agonists
Obesity
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
MHRA DSU Dec 2025: Rybelsus ® (semaglutide tablets): transition to new formulation and risk of medication error
MHRA DSU Nov 2023 Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products
MHRA DSU: Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
NICE TA875: Semaglutide for managing overweight and obesity